TY - JOUR
T1 - Trends in use and expenditures of brand-name atorvastatin after introduction of generic atorvastatin
AU - Warraich, Haider J.
AU - Salami, Joseph A.
AU - Khera, Rohan
AU - Valero-Elizondo, Javier
AU - Okunrintemi, Victor
AU - Nasir, Khurram
N1 - Funding Information:
Funding/Support: The data used in this analysis were obtained from The Dartmouth Atlas, which is funded by the Robert Wood Johnson Foundation and the Dartmouth Clinical and Translational Science Institute, under award No. UL1TR001086 from the National Center for Advancing Translational Sciences of the National Institutes of Health.
Funding Information:
Corresponding Author: Jing Luo, MD, MPH, Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120 ([email protected]). Conflict of Interest Disclosures: None reported. Funding/Support: Dr Kesselheim’s work is supported through a grant from the Laura and John Arnold Foundation, with additional support from the Harvard Program in Therapeutic Science and the Engelberg Foundation. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
PY - 2018/5
Y1 - 2018/5
UR - http://www.scopus.com/inward/record.url?scp=85046790329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046790329&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2018.0990
DO - 10.1001/jamainternmed.2018.0990
M3 - Letter
C2 - 29525818
AN - SCOPUS:85046790329
SN - 2168-6106
VL - 178
SP - 719
EP - 721
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
IS - 5
ER -